Modeling approaches for reducing safety-related attrition in drug discovery and development: a review on myelotoxicity, immunotoxicity, cardiovascular toxicity, and liver toxicity-Reference-Cited by-同舟云学术

Modeling approaches for reducing safety-related attrition in drug discovery and development: a review on myelotoxicity, immunotoxicity, cardiovascular toxicity, and liver toxicity

Published:2021-06-28 Issue:11 Volume:16 Page:1365-1390
ISSN:1746-0441
Container-title:Expert Opinion on Drug Discovery
language:en
Short-container-title:Expert Opinion on Drug Discovery

Author:

Tosca Elena M.¹,Bartolucci Roberta¹,Magni Paolo¹,Poggesi Italo²

Affiliation:

1. Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy

2. Clinical Pharmacology & Pharmacometrics, Janssen Research & Development, Beerse, Belgium

Funder

manuscript was not funded

Publisher

Informa UK Limited

Subject

Drug Discovery

Link

https://www.tandfonline.com/doi/pdf/10.1080/17460441.2021.1931114

Reference168 articles.

1. Evolving Roles of Spontaneous Reporting Systems to Assess and Monitor Drug Safety

2. An analysis of the attrition of drug candidates from four major pharmaceutical companies

3. Investigative safety strategies to improve success in drug development

4. Redfern W, Ewart L, Hammond T, et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle. 49th Annual Meeting of the Society of Toxicology, Salt Lake City, March 7–11, 2010, abstract 1081.

5. Drug Safety Sciences and the Bottleneck in Drug Development

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MultiCBlo: Enhancing predictions of compound-induced inhibition of cardiac ion channels with advanced multimodal learning;International Journal of Biological Macromolecules;2024-09

2. Model‐Informed Reinforcement Learning for Enabling Precision Dosing Via Adaptive Dosing;Clinical Pharmacology & Therapeutics;2024-07-11

3. The estimation and translation uncertainties in applying NOAEL to clinical dose escalation;Clinical and Translational Science;2024-05-29

4. In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients;CPT: Pharmacometrics & Systems Pharmacology;2024-02-07

5. TheMarker: a comprehensive database of therapeutic biomarkers;Nucleic Acids Research;2023-10-18